[go: up one dir, main page]

YU60301A - N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karboksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije - Google Patents

N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karboksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije

Info

Publication number
YU60301A
YU60301A YU60301A YUP60301A YU60301A YU 60301 A YU60301 A YU 60301A YU 60301 A YU60301 A YU 60301A YU P60301 A YUP60301 A YU P60301A YU 60301 A YU60301 A YU 60301A
Authority
YU
Yugoslavia
Prior art keywords
treatment
insulin resistance
pathological
piperidinyl
propoxy
Prior art date
Application number
YU60301A
Other languages
English (en)
Inventor
Maria Kurthy
Katalin Biro
Karoly Nagy
Laszlo Urogdi
Zita Csakai
Jeno Szilbereky
Tamas Mogyorosi
Magdolna Torok
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Es Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Es Fejleszto Rt. filed Critical Biorex Kutato Es Fejleszto Rt.
Publication of YU60301A publication Critical patent/YU60301A/sh
Publication of RS50083B publication Critical patent/RS50083B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na N/2-hidroksi-3-(1-piperidinil)-propoksi/-piridin-1-oksid-3-karboksiimidoil hlorid, njegove stereoizomere i adiciona soli sa kiselinama otuda, farmaceutske kompozicije koje sadrže iste, na upotebu ovih jedinjenja u tretiranju patološke insulinske rezistencije, i za tretiranje patoloških stanja povezanih sa ovime, za tretiranje patološke insulinske rezistencije, i za tretiranje patoloških stanja povezanih sa ovime, pomoću stimulativnog tretiranja i prevencije dijabetesom izazvanih hroničnih komplikacija, naročito retinopatije, neuropatije i nefropatije i/ili sa stimulativnim povećanjem patološkog opadanja periferne neuroregulacije izazvane dijabeteson i na postupke tretiranja.
YUP-603/01A 1999-02-26 2000-02-24 N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karbo ksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije RS50083B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Publications (2)

Publication Number Publication Date
YU60301A true YU60301A (sh) 2004-05-12
RS50083B RS50083B (sr) 2009-01-22

Family

ID=90014224

Country Status (27)

Country Link
US (1) US6649628B1 (sh)
EP (1) EP1163224B1 (sh)
JP (1) JP4689838B2 (sh)
KR (1) KR100676124B1 (sh)
AT (1) ATE237590T1 (sh)
AU (1) AU779096B2 (sh)
BG (1) BG65178B1 (sh)
BR (1) BR0008969A (sh)
CA (1) CA2360451C (sh)
CZ (1) CZ297386B6 (sh)
DE (1) DE60002187T2 (sh)
DK (1) DK1163224T3 (sh)
EE (1) EE04961B1 (sh)
ES (1) ES2193055T3 (sh)
HR (1) HRP20010584B1 (sh)
HU (1) HUP9900475D0 (sh)
IL (2) IL144866A0 (sh)
NO (1) NO319793B1 (sh)
PL (1) PL197692B1 (sh)
PT (1) PT1163224E (sh)
RS (1) RS50083B (sh)
RU (1) RU2250901C2 (sh)
SI (1) SI1163224T1 (sh)
SK (1) SK287063B6 (sh)
UA (1) UA72495C2 (sh)
WO (1) WO2000050403A1 (sh)
ZA (1) ZA200106488B (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
JP2005514418A (ja) 2002-01-11 2005-05-19 ビオレックス クタトー エス フェイレストェー アールテー． カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
WO2010058779A1 (ja) 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
JP2013544263A (ja) 2010-11-30 2013-12-12 オルファザイム エーピーエス Ｈｓｐ７０の細胞内活性を上昇させる方法
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
AU2013312981B2 (en) * 2012-09-06 2017-06-22 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
EP2896269B2 (de) 2012-09-14 2020-06-03 Saint-Gobain Glass France Scheibe mit einem elektrischen anschlusselement
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
JP6678676B2 (ja) * 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
PT3448382T (pt) 2016-04-29 2020-11-20 Orphazyme As C/O Cobis As Arimoclomol para o tratamento de distúrbios associados à glucocerebrosidase
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
BR112020024182A2 (pt) 2018-05-28 2021-03-30 Orphazyme A/S Métodos para detectar proteína de choque térmico 70, para diagnosticar uma doença apresentando um nível reduzido de proteína de choque térmico 70, para selecionar um paciente tendo uma doença apresentando um nível reduzido de hsp70, para monitorar progressão de doença em um indivíduo, para monitorar a eficácia de uma terapia para tratamento de uma doença, e, para ajustar a dosagem de um derivado de hidroxilamina de molécula pequena.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
MX2023000033A (es) 2020-06-24 2023-04-10 Kempharm Denmark As Arimoclomol para tratar la enfermedad de gaucher.
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
IL303026A (en) * 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof
WO2022136640A1 (en) 2020-12-24 2022-06-30 Orphazyme A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
CA2360451C (en) 2011-01-04
BR0008969A (pt) 2001-11-27
HUP9900475D0 (en) 1999-04-28
CZ297386B6 (cs) 2006-11-15
HRP20010584B1 (en) 2010-08-31
ATE237590T1 (de) 2003-05-15
IL144866A0 (en) 2002-06-30
KR100676124B1 (ko) 2007-01-31
CZ20013053A3 (cs) 2002-01-16
IL144866A (en) 2007-07-04
WO2000050403A1 (en) 2000-08-31
EP1163224B1 (en) 2003-04-16
HRP20010584A2 (en) 2002-08-31
RU2250901C2 (ru) 2005-04-27
DE60002187D1 (de) 2003-05-22
US6649628B1 (en) 2003-11-18
PL350915A1 (en) 2003-02-10
BG65178B1 (bg) 2007-05-31
PT1163224E (pt) 2003-07-31
KR20010102410A (ko) 2001-11-15
EE200100447A (et) 2002-12-16
ES2193055T3 (es) 2003-11-01
NO20014103L (no) 2001-10-22
RS50083B (sr) 2009-01-22
JP4689838B2 (ja) 2011-05-25
EE04961B1 (et) 2008-02-15
NO20014103D0 (no) 2001-08-23
CA2360451A1 (en) 2000-08-31
DE60002187T2 (de) 2003-12-11
SK11582001A3 (sk) 2001-12-03
PL197692B1 (pl) 2008-04-30
AU3182400A (en) 2000-09-14
BG105837A (en) 2002-03-29
EP1163224A1 (en) 2001-12-19
SK287063B6 (sk) 2009-10-07
SI1163224T1 (en) 2003-08-31
UA72495C2 (uk) 2005-03-15
AU779096B2 (en) 2005-01-06
JP2002537384A (ja) 2002-11-05
NO319793B1 (no) 2005-09-12
DK1163224T3 (da) 2003-08-04
ZA200106488B (en) 2002-08-07

Similar Documents

Publication Publication Date Title
YU60301A (sh) N-/2-hidroksi-3-(1-piperidinil) propoksi/piridin-1-oksid- 3-karboksimidoil hlorid i njegova upotreba u tretiranju insulinske rezistencije
MEP25408A (en) Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
IL113894A0 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives process for their preparation pharmaceutical compositions containing them and their use
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
MY135920A (en) New phenalkyloxy-phenyl derivatives
SE9904421D0 (sv) New compounds
SE9903894D0 (sv) Novel compounds
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
ATE251614T1 (de) Piperazinderivate als neurokinin-antagonisten
PL323235A1 (en) Derivatives of piperazine as neurokinin antagonists
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
ATE250427T1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
SE0101978D0 (sv) New compounds
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
DK1187824T3 (da) Derivater (2-substitueret-5-[3-thienyl])benzyl-[2-([2-isopropoxy-5-flour]phenoxy)ethylamin, fremgangsmåde til fremstilling deraf og anvendelse deraf som medikamenter
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
DE60011711D1 (de) Pyrroloazepinderivate enthaltende arzneimittel zur behandlung von claudicatio intermittens